Efficacy of Dengue Vaccines in the Prevention of Severe Dengue in Children: A Systematic Review

Abstract

Dengue is a vector-borne disease caused by the dengue virus (DENV) and is a major health concern worldwide, particularly in regions of endemic disease. Dengue usually presents as a self-limited febrile illness. In some cases, more severe forms with hemorrhage and shock can occur, and children are especially prone to develop it. These forms can be lethal without appropriate management, and no antiviral treatment exists today. In the absence of a curative treatment for dengue, its clinical prevention remains essential. One vaccine -the chimeric yellow fever-dengue-tetravalent dengue vaccine (CYD-TDV) -has been approved for use in some populations, and several others are currently in development, including Takeda's tetravalent dengue vaccine candidate (TAK-003).This study is a systematic review of the current literature realized to evaluate the efficacy of the dengue vaccines in preventing severe dengue in children. This review focuses on the vaccines CYD-TDV and TAK-003. This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed, PubMed Central (PMC), Medical Literature Analysis and Retrieval System Online (MEDLINE), Cochrane Library, and Google Scholar were the databases used to find the relevant data. The articles were selected using specific inclusion and exclusion criteria, and quality appraisal was realized with standardized quality assessment tools. Overall, our study shows that the dengue vaccines CYD-TDV and TAK-003 confer protection against severe dengue in children. Some distinctions exist depending on the vaccine type, the age, and the dengue serostatus of patients. While demonstrating encouraging results, this review also emphasizes the need for more in-depth studies about the safety and efficacy of dengue vaccines.

Assessing Dengue Virus Importation Risks in Africa: A Climate and Travel-Based Model

“…For dengue, molecular surveillance also allows public officials to monitor the circulating serotypes while remaining vigilant for the emergence of novel strains or genotypes. At present, there is no approved antiviral treatment for dengue and supportive care is the only option (17–19). However, two dengue vaccines have shown great promise (Takeda and Butantan vaccines) (20).…”

Evaluation of a Chatbot Powered by ChatGPT for the Preliminary Diagnosis of Dengue

“…However, in some cases, more severe forms of dengue can occur, with symptoms of hemorrhage and shock, especially in children. These variants can be fatal if not properly managed, and no effective antiviral treatment has been found to combat them [11]. According to Liao [12], individuals affected by dengue fever often present with a fever and rash.…”

Expression of global consensus non-structural protein 1 (NS1) of dengue virus serotypes 1 and 2 in Nicotiana benthamiana

“…The dengue virus heterogenicity and antibody enhancement are the main roadblocks toward developing effective vaccines against Dengue. While vaccines from reputable sources such as Sanofi, NIAID, and Takeda have recently been approved, unfortunate incidents during their implementation in children of certain countries have raised significant concerns, thus hindering the widespread adoption of these vaccines (Foucambert et al, 2022).…”